Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
2009 · The Lancet · 1,345 citations
https://doi.org/10.1016/s0140-6736(09)60500-6
J
Jonathan Polikoff
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
84
Papers
13.8K
Citations
31
h-index
49
i10-index
Jonathan Polikoff is an academic researcher from Kaiser Permanente. The author has contributed to research in topics: Cancer Treatment and Pharmacology & Lymphoma Diagnosis and Treatment & Breast Cancer Treatment Studies. The author has an h-index of 31, co-authored 72 publications.
Papers by this author
worksPertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
2020 · The Lancet Oncology · 865 citations
https://doi.org/10.1016/s1470-2045(19)30863-0
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+
2019 · Journal of Clinical Oncology · 410 citations
https://doi.org/10.1200/jco.19.01455
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE
2021 · Annals of Oncology · 119 citations
https://doi.org/10.1016/j.annonc.2021.04.011
Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43
2013 · Breast Cancer Research and Treatment · 74 citations
https://doi.org/10.1007/s10549-013-2755-z
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5
2016 · Clinical Breast Cancer · 10 citations
https://doi.org/10.1016/j.clbc.2016.07.008
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat